top of page


CAR density influences CAR-T antitumoral efficacy and correlates with clinical outcome

P Rodríguez-Márquez(1) M E Calleja-Cervantes(1,2) G Serrano(2) M L Palacios-Berraquero(3) P San Martin-Uriz(1) A Vilas-Zornoza(1,10) A Martín-Mallo(1) S Rodríguez-Diaz(1) R Martínez-Turrillas(1,10) P Jauregui(5) C Calviño(5) S Inoges(5,6,10) A López-Díaz de Cerio(5,6,10) A Oliver-Caldés(7) M Español(8) M Pascal(8) B Martin-Antonio(7) M Juan(8) A Urbano-Ispizua(7) C Fernández de Larrea(7) M C Viguria(4) M Redondo(4) P Rodriguez-Otero(3) J Rifon(3,5,10) A Alfonso(3,10) T Lozano(9) J J Lasarte(9) M Hernaez(2,10) J R Rodríguez-Madoz(1,10) F Prósper(1,3,5,10)

1:Hemato-Oncology Program. CIMA Universidad de Navarra. IdiSNA. Pamplona, 31008. Spain; 2:Computational Biology Program. CIMA Universidad de Navarra. IdiSNA. Pamplona, 31008. Spain; 3:Hematology and Hemotherapy Department. Clínica Universidad de Navarra. Pamplona, 31008. Spain; 4:Hematology Service, Complejo Hospitalario de Navarra. IdiSNA. Pamplona, 31008, Spain.; 5:Cell Therapy Area. Clínica Universidad de Navarra. IdiSNA. Pamplona, 31008. Spain.; 6:Immunology and Immunotherapy Department, Clínica Universidad de Navarra. Pamplona, 31008. Spain.; 7:Department of Hematology, Hospital Clinic, IDIBAPS, Barcelona, 08036, Spain; 8:Department of Immunotherapy, Hospital Clinic, IDIBAPS, Barcelona, 08036, Spain; 9:Immunology and Immunotherapy Program. CIMA Universidad de Navarra. IdiSNA. Pamplona, 31008. Spain.; 10:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC). Madrid, 28029. Spain.

Recent studies have shown that control of CAR expression influences CAR-T efficacy. Therefore, we hypothesized that CAR density directly affects CAR-T cell function. In this study we characterized the in vitro and in vivo antitumoral efficacy of FACS-isolated subpopulations of CAR-T cells with different CAR densities targeting BCMA. CARHigh-T cells presented increased basal activation together with more differentiated phenotypes, increased cytotoxicity and cytokine production against multiple myeloma cell lines. This effect was also observed in the infusion products of a clinical trial, where products enriched in CARHigh-T cells presented increased cytotoxicity. After antigen-driven activation, higher presence of terminally differentiated effector cells was observed in CARHigh-T cells, along with increased exhaustion. In vivo, CARLow-T cells presented increased persistence, suggesting that higher CAR levels could reduce long-term efficacy. Transcriptomic analysis revealed completely different expression profiles, with increased tonic signal in CARHigh-T cells. We generated a gene signature associated to CAR density to annotate CARHigh-T cells in scRNA-seq analysis to further infer regulatory dissimilarities driven by different CAR densities, using novel computational methods. Finally, to evaluate the impact of CAR density in the clinical outcome of CAR-T therapies, we applied the inferred gene signature to score infusion products from a clinical trial, observing absence of complete responders in those products enriched on CARHigh signature.

Our data demonstrate that CAR density plays important roles in CAR-T activity with impact on clinical outcome. Comprehension of regulatory mechanisms driven by CAR densities at the single cell level offer an important tool for the development of improved therapies.

bottom of page